Lupus & antiphospholipid syndrome
Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?
Authors' conclusion
Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) receiving belimumab, Pisa SLE cohortfrom 422 in cohort
- Participants
- 102 patients
- Exposure
- Immunosuppressant (IS)-naïve vs prior conventional IS before belimumab
- IS-naïven = 22
- Outcome
- LLDAS5 and remission with BEL (whole cohort)
- Follow-up
- 6 and 12 months
Methodological detailsretrospective analysis of prospectively collected data, monocentric
- Retrospective analysis of prospectively collected data
- Monocentric
Main finding
As reported in the abstract
6 and 12 months
LLDAS5 at 6 months
47%
Remission at 6 months
38%
LLDAS5 at 12 months
75%
Remission at 12 months
66%
Observational data: associations, not effects.
Further findings
Baseline characteristics, LLDAS5 and remission, IS-naïve vs prior IS
- No significant differences in baseline characteristics or achievement of LLDAS5 and remission
Glucocorticoid (GC) daily dose, IS-naïve vs prior IS · 6 and 12 months
- No significant difference in mean GC daily dose at baseline; IS-naïve took significantly lower GC daily dose at 6 and 12 months
Prescription trend
- IS-naïve patients more common in the most recent years
Original publication
Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use? RMD Open. Published 12 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →